Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
March 18, 2021Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
March 17, 2021Targovax ASA announces new member of the Board
March 17, 2021Targovax ASA: Minutes from the Annual General Meeting
March 9, 2021Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors